-
Quality of Life Assessment of Patients Undergoing Hip Replacement Surgery in the Public and Private Healthcare Systems
Mar 10, 2025, 14:00 PM -
Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population
Mar 10, 2025, 14:00 PM -
Extended MAIC to Validate Results in Cases of Poor Population Overlap: An Application to Compare Prophylactic Treatments in Pediatric Patients With Hemophilia A
Mar 10, 2025, 14:00 PM -
Temporal Trends in Emergency Department Utilization for Opioid Use Disorder in Baltimore, Maryland
Mar 10, 2025, 14:00 PM -
Natural History and Burden of Disease Among Patients With Juvenile GM2 Gangliosidoses in France
Mar 10, 2025, 14:00 PM -
Changes in Respiratory Medication and Antibiotic Use Among Asthma and COPD Individuals During the Pandemic
Mar 10, 2025, 14:00 PM -
Complete Economic Evaluation Publications for Acupuncture
Mar 10, 2025, 14:00 PM -
Psychometric Validation of the Sunlight Exposure Diary and Erythropoietic Protoporphyria Impact Questionnaire (EPIQ) Using Data from the AURORA Clinical Study in Erythropoietic Protoporphyria (EPP)
Mar 10, 2025, 14:00 PM -
Association between Exposure to GLP-1 Treatment and Pancreatitis Risk in Obesity Patients: A Retrospective Database Study
Mar 10, 2025, 14:00 PM -
Frailty Indices Using Claims Data - Examples from a Hospitalized Medicare Population
Mar 10, 2025, 14:00 PM -
Developing a Large Language Model-Based Simulation for P&T Committees: Methodology and Inputs for Realistic Dynamics
Mar 10, 2025, 14:00 PM -
Burden of Illness and Healthcare Resource Utilization (HCRU) for Chronic Obstructive Pulmonary Disease (COPD) in Ontario, Canada
Mar 10, 2025, 14:00 PM -
The Impact of Family Spillover Effects in Economic Evaluation for SMA Type 1 Treatments in the United States
Mar 10, 2025, 14:00 PM -
Temporal Trends in Prescription of GLP-1RAs for Weight Loss: Insights From a Five-Year Retrospective Analysis in the US
Mar 10, 2025, 14:00 PM -
Use of Artificial Intelligence for Rapid Epidemiology Reviews With Pooled Prevalence and Incidence Estimates
Mar 10, 2025, 14:00 PM -
A Checklist to Facilitate Reporting of Real-World Evidence (RWE) Submitted to Canada's Drug Agency (CDA-AMC) for a Drug Product Under Review
Mar 10, 2025, 14:00 PM -
Who Benefits From Technological Progress Among People With Type 1 Diabetes? Improvements in Glycemic Outcomes After CGM Adoption by Sociodemographic Characteristics
Mar 10, 2025, 14:00 PM -
A Cost-Effectiveness Analysis of Diagnostic Testing in Alzheimer's Disease
Mar 10, 2025, 14:00 PM -
A Comprehensive Review of Real-World Evidence (RWE) Use in Submissions to Canada's Drug Agency (CDA)
Mar 10, 2025, 14:00 PM -
Disease Burden Estimates in Economic Evaluation Studies of Respiratory Syncytial Virus (RSV) Maternal Immunization: A Systematic Review
Mar 10, 2025, 14:00 PM
